ConvaTec Group (LON:CTEC) had its target price boosted by JPMorgan Chase & Co. from GBX 167 ($2.06) to GBX 172 ($2.12) in a report published on Tuesday morning, Stock Target Advisor reports. They currently have an underweight rating on the stock.
Other research analysts have also issued reports about the company. Citigroup reaffirmed a neutral rating on shares of ConvaTec Group in a research report on Thursday, June 18th. UBS Group boosted their price target on ConvaTec Group from GBX 235 ($2.89) to GBX 245 ($3.02) and gave the company a buy rating in a research note on Friday, May 1st. Royal Bank of Canada upgraded ConvaTec Group to an outperform rating and boosted their price target for the company from GBX 178 ($2.19) to GBX 245 ($3.02) in a research note on Wednesday, June 10th. Barclays upped their target price on ConvaTec Group from GBX 182 ($2.24) to GBX 190 ($2.34) and gave the stock an equal weight rating in a research note on Monday, May 18th. Finally, Credit Suisse Group upped their target price on ConvaTec Group from GBX 175 ($2.15) to GBX 180 ($2.22) and gave the stock an underperform rating in a research note on Friday, May 1st. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. ConvaTec Group has an average rating of Hold and a consensus price target of GBX 214 ($2.63).
Shares of LON:CTEC opened at GBX 195.60 ($2.41) on Tuesday. The business’s 50-day moving average is GBX 206.26 and its 200 day moving average is GBX 198.02. ConvaTec Group has a 1 year low of GBX 140.40 ($1.73) and a 1 year high of GBX 225.80 ($2.78). The firm has a market capitalization of $3.96 billion and a P/E ratio of 391.20. The company has a debt-to-equity ratio of 100.87, a current ratio of 2.44 and a quick ratio of 1.64.
ConvaTec Group Company Profile
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as for traumatic injury, burns, invasive surgery, and other causes.
Recommended Story: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.